🟣‼️ 在 #ESMO26 上，刚刚发布了关于早期 HR+/HER2− 高复发风险 #cáncerdemama 的新且显著结果。
📉 六年随访结果显示，与单纯内分泌治疗相比，死亡风险降低了 19,1%。此外，#supervivencia global 获益随时间持续增加，并在治疗结束多年后仍保持。六年时侵袭性疾病无病生存的绝对差异达到 5,3%，而五年时为 4,1%。
🧪 西班牙在取得这些结果中发挥了关键作用，得益于 @GEICAM - Spanish Breast Cancer Group 的协调，参与了 12 个自治区的 47 家医院和 761 例患者，占研究总样本的 15% 🔝 我国因此成为欧洲第一、全球第二大患者贡献国。
🤝 GEICAM 想要强调患者、临床研究者及参与中心的贡献，他们的承诺使得 #investigación del cáncer de mama 持续进步。
🟣 #ESMO2026
🔬 @myESMO - European Society for Medical Oncology
281 浏览 · 4 赞 · 4 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：GEICAM - Cáncer de mama · x.com